|
Getting your Trinity Audio player ready...
|
Dyadic International, Inc. (NASDAQ: DYAI) Chief Executive Officer, Mark Emalfarb, appeared on “The Street Podcast” for an in-depth conversation about the company. During the interview, he highlighted that Dyadic had achieved success in creating an affordable, adaptable, and scalable protein production system, which the company subsequently sold to DuPont for $75 million. Also, CEO highlights C1 Platform’s Game-Changing Impact Drawing Parallels to Tesla, Inc.’s (NYSE: TSLA) Automotive Industry Transformation among other 2024 company expectations. Listen Now!
Dyadic’s stock has been consolidating in the mid $1.60’s per share, representing a 21.48% increase March 2024. Currently, it is trading above its 10-day, 20-day, and 50-day moving averages (DMA), and is nearing its 200 DMA at $1.73 per share. If the stock surpasses its 200 DMA, it could potentially challenge its 52-week high of $2.40, making it a stock worth keeping an eye on in the near term.
Additionally, Dyadic International, Inc. (NASDAQ: DYAI) revealed the online publication of a manuscript titled “Filamentous fungus-produced human monoclonal antibody provides protection against SARS-CoV-2 in hamster and nonhuman primate models.” This significant publication appeared in Nature Communications, a renowned global journal renowned for publishing peer-reviewed research across various science and technology domains. Read Journal Review Now!
The findings disclosed in the manuscript served as evidence of the promising potential of Dyadic International’s C1 Expression system as a technology platform for human monoclonal antibody development and the production of therapeutic and preventive medications. This is the first trial using a C1-produced monoclonal antibody demonstrated comparable protection against SARS-CoV-2 in hamster and nonhuman primate models when compared to antibodies produced in CHO.
Furthermore, Dyadic recently concluded its participation in the Future Food Tech conference, emphasizing the advancement of sustainable and healthy food ecosystems. The event featured 1700 distinguished global food brands including Archer-Daniels-Midland Co. (NYSE: ADM), Kraft Heinz Co (NASDAQ: KHC), Ginkgo Bioworks Holdings, Inc. (NYSE: DNA), Beyond Meat Inc. (NASDAQ: BYND), and others.
Related posts:
“Dyadic International (NASDAQ: DYAI) Revolutionizing Pharma with Innovative C1 Technology for Global Protein Development”
Bull Run 2024: Biopharma Healthcare Stocks Surge, Gaining Momentum: DYAI, ABVC, FWBI, VTAK, NEXI
Biopharmaceutical Advancements: Dyadic (Nasdaq: DYAI) Raises Industry Standards with Maravai LifeSciences’ (Nasdaq: MRVI) Cygnus Technologies
Recent Market Movers: Healthcare Companies Making Headlines: DYAI, RIGL, ARDX, VERO, MEDS
Biotech Breakthroughs: Dyadic International (NASDAQ: DYAI) Partners with Rabian BV to Combat Rabies